UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_____________

FORM 8-K

_____________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): October 20, 2016

Checkpoint Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

(State or Other Jurisdiction

of Incorporation)

000-55506

(Commission File Number)

47-2568632

(IRS Employer Identification No.)

2 Gansevoort Street, 9th Floor

New York, New York

(Address of Principal Executive Offices)

(781) 652-4500

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act.

Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

-1 -

Item 8.01. Other Events.

On October 20, 2016, Checkpoint Therapeutics, Inc.’s parent company, Fortress Biotech, Inc., posted a presentation including an updated corporate overview to its website. A copy of the presentation is being filed as Exhibit 99.1 and incorporated in this Item by reference.

Item 9.01 Financial Statements And Exhibits.

(d)

Exhibits.

99.1

Investor Presentation, dated October 20, 2016.

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Checkpoint Therapeutics, Inc.
	(Registrant)


Date: October 20, 2016


	By:	/s/ James F. Oliviero
		James F. Oliviero President and Chief Executive Officer

- 3 -

INDEX TO EXHIBITS

Exhibit

Number

Description

99.1

Investor Presentation, dated October 20, 2016.

- 4 -